Tags

Type your tag names separated by a space and hit enter

Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Aliment Pharmacol Ther 2005; 22(5):373-80AP

Abstract

BACKGROUND

Tegaserod is a promotility agent with proven efficacy and safety in patients with irritable bowel syndrome with constipation.

AIM

To assess tegaserod's effect on work productivity and daily activity.

METHODS

Women, 18-65 years old and meeting Rome II criteria for irritable bowel syndrome with constipation, were randomized to a double-blind, placebo-controlled, multicentre study of tegaserod 6 mg b.d. or placebo. Productivity loss and daily activity impairment because of irritable bowel syndrome were measured with the Work Productivity and Activity Impairment questionnaire for irritable bowel syndrome, modified to exclude diarrhoea as a symptom. Assessments were made at baseline, weeks 2 and 4.

RESULTS

A total of 2660 women were randomized and, of these, 1675 [tegaserod (n = 1363), placebo (n = 312)] were employed and completed Work Productivity and Activity Impairment for irritable bowel syndrome questionnaires. Compared with placebo, tegaserod significantly reduced work and daily activity impairment at weeks 2 and 4. Tegaserod reduced absenteeism by 2.6% (P = 0.004), presenteeism by 5.4% (P < 0.0001), overall work productivity loss by 6.3% (P < 0.0001), and activity impairment by 5.8% (P < 0.0001) at week 4 (vs. baseline). Assuming a 40-h workweek, tegaserod reduced work productivity loss by 2.5 h/week.

CONCLUSIONS

Tegaserod significantly reduced work productivity loss and daily activity impairment at 2 weeks, and this benefit was maintained at 4 weeks.

Authors+Show Affiliations

Margaret Reilly Associates, Inc., New York, NY, USA. mreilly@reillyassociates.netNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16128674

Citation

Reilly, M C., et al. "Effect of Tegaserod On Work and Daily Activity in Irritable Bowel Syndrome With Constipation." Alimentary Pharmacology & Therapeutics, vol. 22, no. 5, 2005, pp. 373-80.
Reilly MC, Barghout V, McBurney CR, et al. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2005;22(5):373-80.
Reilly, M. C., Barghout, V., McBurney, C. R., & Niecko, T. E. (2005). Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics, 22(5), pp. 373-80.
Reilly MC, et al. Effect of Tegaserod On Work and Daily Activity in Irritable Bowel Syndrome With Constipation. Aliment Pharmacol Ther. 2005 Sep 1;22(5):373-80. PubMed PMID: 16128674.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. AU - Reilly,M C, AU - Barghout,V, AU - McBurney,C R, AU - Niecko,T E, PY - 2005/9/1/pubmed PY - 2005/11/15/medline PY - 2005/9/1/entrez SP - 373 EP - 80 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 22 IS - 5 N2 - BACKGROUND: Tegaserod is a promotility agent with proven efficacy and safety in patients with irritable bowel syndrome with constipation. AIM: To assess tegaserod's effect on work productivity and daily activity. METHODS: Women, 18-65 years old and meeting Rome II criteria for irritable bowel syndrome with constipation, were randomized to a double-blind, placebo-controlled, multicentre study of tegaserod 6 mg b.d. or placebo. Productivity loss and daily activity impairment because of irritable bowel syndrome were measured with the Work Productivity and Activity Impairment questionnaire for irritable bowel syndrome, modified to exclude diarrhoea as a symptom. Assessments were made at baseline, weeks 2 and 4. RESULTS: A total of 2660 women were randomized and, of these, 1675 [tegaserod (n = 1363), placebo (n = 312)] were employed and completed Work Productivity and Activity Impairment for irritable bowel syndrome questionnaires. Compared with placebo, tegaserod significantly reduced work and daily activity impairment at weeks 2 and 4. Tegaserod reduced absenteeism by 2.6% (P = 0.004), presenteeism by 5.4% (P < 0.0001), overall work productivity loss by 6.3% (P < 0.0001), and activity impairment by 5.8% (P < 0.0001) at week 4 (vs. baseline). Assuming a 40-h workweek, tegaserod reduced work productivity loss by 2.5 h/week. CONCLUSIONS: Tegaserod significantly reduced work productivity loss and daily activity impairment at 2 weeks, and this benefit was maintained at 4 weeks. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/16128674/Effect_of_tegaserod_on_work_and_daily_activity_in_irritable_bowel_syndrome_with_constipation_ L2 - https://doi.org/10.1111/j.1365-2036.2005.02577.x DB - PRIME DP - Unbound Medicine ER -